人尿激肽原酶治疗急性脑梗死的疗效观察  

Curative effects of human urinary kallidinogenase on acute cerebral infarction

作　　者：陈海鹰[1] 陈海挺[1] 

机构地区：[1]厦门市第三医院神经内科,福建厦门361100

出　　处：《海南医学院学报》2010年第9期1167-1169,共3页Journal of Hainan Medical University

基　　金：海南医学院科研基金资助学报项目(0020100324)~~

摘　　要：目的:观察人尿激肽原酶治疗急性脑梗死(ACI)的疗效。方法:68例ACI患者随机分为治疗组和对照组,每组各34例。治疗组用人尿激肽原酶0.15PNAu加入生理盐水250mL静脉滴注,每天1次,连用7d;对照组除人尿激肽原酶外,余治疗均同治疗组。治疗前、后进行NIHSS评分,评定临床疗效,并观察不良反应。结果:治疗组治疗后7d和14d时NIHSS评分均显著低于对照组(P均<0.05);治疗组治疗14d后显效率和有效率均明显高于对照组(P均<0.05)。结论:人尿激肽原酶治疗急性脑梗死有显著疗效,且无明显不良反应。Objective：To evaluate the effects of human urinary kallidinogenase on acute cerebral infarction（ACI）.Methods：A total of 68 ACI patients were randomly divided into treatment group and control group with 34 in each.The treatment group was given human urinary kallidinogenase by drop at a dose of 0.15 PNAu,once per day for 7 days,the control group was given the same regime except human urinary kallidinogenase.The National Instiutes of Health Stroke Scale（NIHSS）were tested before and after treatment and efficiency was evaluated.The adverse reaction was also observed during the course of treatment.Results：After 7 days and 14 days of treatment,NIHSS in the treatment group was significantly lower than those of the control group（all P〈0.05）.The excellent effect rate and effective rate of the treatment group were obviously higher than those of the control group（all P〈0.05）.Conclusion：Human urinary kallidinogenase is remarkable effective on ACI and has no obvious adverse reaction.

关 键 词：人尿激肽原酶 急性脑梗死 临床疗效 

分 类 号：R743[医药卫生—神经病学与精神病学]